LENZ Therapeutics Business Summary

LENZ Therapeutics, Inc. (LENZ) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of ophthalmic therapies, primarily targeting presbyopia. The company generates revenue through direct product sales of its lead asset, VIZZ (aceclidine ophthalmic solution 1.44%), which received FDA approval in July 2025 and commenced U.S. commercial launch in October 2025. LENZ also utilizes a licensing and partnership model to expand its global footprint, recently securing international commercialization agreements in the Middle East and other key territories. As of early 2026, the company operates within a highly competitive landscape alongside AbbVie (Vuity), Orasis Pharmaceuticals (Qlosi), and Tenpoint Therapeutics (Yuvezzi). LENZ differentiates itself as the provider of the first and only aceclidine-based miotic, offering a superior duration of effect (up to 10 hours) and a pupil-selective mechanism that avoids the ciliary muscle overstimulation common in pilocarpine-based competitors. The leadership team is anchored by President and CEO Eef (Evert) Schimmelpennink, who brings a robust pedigree from his previous roles as CEO of Pfenex (acquired by Ligand) and Alvotech. The executive suite includes CFO Dan Chevallard, formerly of Viracta and Regulus Therapeutics, and Chief Medical Officer Dr. Marc Odrich, an Associate Professor of Ophthalmology at the University of Virginia with extensive consulting experience at Johnson & Johnson Vision. The company was founded by Dr. Gerald Horn, a prolific ophthalmic innovator. LENZ is supported by a high-profile Board of Directors chaired by Jeffrey P. George, the former CEO of Alcon and Sandoz, and includes representatives from notable institutional investors such as RA Capital Management, Versant Ventures, and Sectoral Asset Management. Other significant backing has been provided by Alpha Wave Global and Franklin Resources, reflecting strong institutional confidence in the company's commercial trajectory.